Acumen Pharmaceuticals Stock Performance
| ABOS Stock | USD 3.57 0.17 5.00% |
On a scale of 0 to 100, Acumen Pharmaceuticals holds a performance score of 2. The firm shows a Beta (market volatility) of -0.46, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Acumen Pharmaceuticals are expected to decrease at a much lower rate. During the bear market, Acumen Pharmaceuticals is likely to outperform the market. Please check Acumen Pharmaceuticals' value at risk, as well as the relationship between the skewness and day median price , to make a quick decision on whether Acumen Pharmaceuticals' price patterns will revert.
Risk-Adjusted Performance
2 of 100
Weak | Strong |
Insignificant
Compared to the overall equity markets, risk-adjusted returns on investments in Acumen Pharmaceuticals are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively unfluctuating basic indicators, Acumen Pharmaceuticals unveiled solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 1.19 | Five Day Return (5.03) | Year To Date Return (19.62) | Ten Year Return (83.08) | All Time Return (83.08) |
1 | Acquisition by Ives Jeffrey L of 25000 shares of Acumen Pharmaceuticals subject to Rule 16b-3 | 06/07/2023 |
2 | Purchase by Ra Capital Management Lp of 5161290 shares of Acumen Pharmaceuticals | 07/25/2023 |
3 | Exercise or conversion by Ives Jeffrey L of 149 shares of Acumen Pharmaceuticals subject to Rule 16b-3 | 08/18/2023 |
4 | Acumen Pharmaceuticals Presents Late-Breaker Phase 1 Updates Exploring Novel Target Engagement, Dosing Regimen and Safety Findings for ACU193 in Early Alzheimer... | 10/27/2023 |
5 | ProMIS Neurosciences Announces Third Quarter 2023 Financial ... - GlobeNewswire | 11/14/2023 |
6 | Sale by Meisner Derek M of 8933 shares of Acumen Pharmaceuticals | 01/19/2024 |
7 | Acumen Pharmaceuticals, Inc. - Special Call Transcript - GuruFocus.com | 02/05/2024 |
8 | Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2023 Financial Results on March 26, 2024 | 03/19/2024 |
9 | Is Acumen Pharmaceuticals Outperforming Other Medical Stocks This Year | 03/21/2024 |
10 | ABOS Stock Earnings Acumen Pharmaceuticals Misses EPS for Q4 2023 | 03/26/2024 |
11 | Acumen Pharmaceuticals, Inc. Q4 2023 Earnings Call Transcript | 03/27/2024 |
12 | Acumen Pharmaceuticals Upgraded to Buy What Does It Mean for the Stock | 03/28/2024 |
13 | Acumen Pharmaceuticals Collaborates with Lonza For Alzheimers Treatment | 04/04/2024 |
14 | Acumen Pharmaceuticals Presents First Comprehensive Clinical and Biomarker Data for Sabirnetug at American Academy of Neurology 2024 Annual Meeting | 04/16/2024 |
15 | Disposition of 131595 shares by Stalfort John A Iii of Acumen Pharmaceuticals subject to Rule 16b-3 | 05/03/2024 |
16 | Acumen Pharmaceuticals to Report First Quarter Results on May 14, 2024 | 05/07/2024 |
| Begin Period Cash Flow | 130.1 M | |
| Free Cash Flow | -43.1 M |
Acumen |
Acumen Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 348.00 in Acumen Pharmaceuticals on February 9, 2024 and sell it today you would earn a total of 9.00 from holding Acumen Pharmaceuticals or generate 2.59% return on investment over 90 days. Acumen Pharmaceuticals is currently generating 0.2365% in daily expected returns and assumes 7.529% risk (volatility on return distribution) over the 90 days horizon. In different words, 66% of stocks are less volatile than Acumen, and 96% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Acumen Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Acumen Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Acumen Pharmaceuticals, and traders can use it to determine the average amount a Acumen Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0314
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ABOS | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 7.53 actual daily | 66 66% of assets are less volatile |
Expected Return
| 0.24 actual daily | 4 96% of assets have higher returns |
Risk-Adjusted Return
| 0.03 actual daily | 2 98% of assets perform better |
Based on monthly moving average Acumen Pharmaceuticals is performing at about 2% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Acumen Pharmaceuticals by adding it to a well-diversified portfolio.
Acumen Pharmaceuticals Fundamentals Growth
Acumen Stock prices reflect investors' perceptions of the future prospects and financial health of Acumen Pharmaceuticals, and Acumen Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Acumen Stock performance.
| Return On Equity | -0.23 | ||||
| Return On Asset | -0.15 | ||||
| Current Valuation | (10.61 M) | ||||
| Shares Outstanding | 60.08 M | ||||
| Price To Book | 0.84 X | ||||
| Price To Sales | 538.78 X | ||||
| Gross Profit | (32.36 M) | ||||
| EBITDA | (60.95 M) | ||||
| Net Income | (52.37 M) | ||||
| Cash And Equivalents | 189.91 M | ||||
| Cash Per Share | 4.69 X | ||||
| Total Debt | 31.05 M | ||||
| Current Ratio | 37.21 X | ||||
| Book Value Per Share | 4.61 X | ||||
| Cash Flow From Operations | (43.06 M) | ||||
| Earnings Per Share | (1.08) X | ||||
| Market Capitalization | 201.87 M | ||||
| Total Asset | 310.12 M | ||||
| Retained Earnings | (222.8 M) | ||||
| Working Capital | 233.64 M | ||||
About Acumen Pharmaceuticals Performance
To evaluate Acumen Pharmaceuticals Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Acumen Pharmaceuticals generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Acumen Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Acumen Pharmaceuticals market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents Acumen's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 0.19 | 0.18 | |
| Return On Tangible Assets | (0.17) | (0.18) | |
| Return On Capital Employed | (0.21) | (0.22) | |
| Return On Assets | (0.17) | (0.18) | |
| Return On Equity | (0.20) | (0.19) |
Things to note about Acumen Pharmaceuticals performance evaluation
Checking the ongoing alerts about Acumen Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Acumen Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Acumen Pharmaceuticals had very high historical volatility over the last 90 days | |
| Net Loss for the year was (52.37 M) with loss before overhead, payroll, taxes, and interest of (32.36 M). | |
| Acumen Pharmaceuticals currently holds about 189.91 M in cash with (43.06 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.69, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Acumen Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| Roughly 72.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from finance.yahoo.com: Acumen Pharmaceuticals to Report First Quarter Results on May 14, 2024 |
- Analyzing Acumen Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Acumen Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Acumen Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Acumen Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Acumen Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Acumen Pharmaceuticals' stock. These opinions can provide insight into Acumen Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Acumen Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in persons. For more information on how to buy Acumen Stock please use our How to Invest in Acumen Pharmaceuticals guide.You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Complementary Tools for Acumen Stock analysis
When running Acumen Pharmaceuticals' price analysis, check to measure Acumen Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Acumen Pharmaceuticals is operating at the current time. Most of Acumen Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Acumen Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Acumen Pharmaceuticals' price. Additionally, you may evaluate how the addition of Acumen Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Transaction History View history of all your transactions and understand their impact on performance | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| CEOs Directory Screen CEOs from public companies around the world |
Is Acumen Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Acumen Pharmaceuticals. If investors know Acumen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Acumen Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.08) | Revenue Per Share 0.033 | Return On Assets (0.15) | Return On Equity (0.23) |
The market value of Acumen Pharmaceuticals is measured differently than its book value, which is the value of Acumen that is recorded on the company's balance sheet. Investors also form their own opinion of Acumen Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Acumen Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Acumen Pharmaceuticals' market value can be influenced by many factors that don't directly affect Acumen Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Acumen Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Acumen Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Acumen Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.